Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 327.4	$ 1,303.4	$ 3,405.5
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,466.3	637.2	407.3
Share-based compensation	318.5	100.3	97.0
Amortization of deferred financing costs	125.5	0.0	0.0
Change in fair value of contingent consideration	11.1	(149.9)	14.7
Unwind of inventory fair value step-up	1,118.0	31.1	91.9
Impairment of intangible assets	8.9	643.7	190.3
Movement in deferred taxes	(594.6)	(198.2)	(14.3)
Write down of PP&E	92.4	0.0	0.0
Other, net	31.4	0.0	(27.9)
Changes in operating assets and liabilities:
Increase in accounts receivable	(701.7)	(211.4)	(66.1)
Increase in sales deduction accruals	288.3	97.6	107.6
Increase in inventory	(255.8)	(63.2)	(25.3)
Decrease/(increase) in prepayments and other assets	(198.4)	37.2	42.4
Increase in accounts and notes payable and other liabilities	621.6	109.2	5.3
Net cash provided by operating activities	2,658.9	2,337.0	4,228.4
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash	62.8	(32.0)	(32.6)
Purchases of subsidiary undertakings and businesses, net of cash acquired	(17,476.2)	(5,553.4)	(4,104.4)
Purchases of non-current investments and PP&E	(648.7)	(124.2)	(100.1)
Proceeds from short-term investments	0.0	67.0	57.8
Proceeds received on sale of product rights	10.9	17.5	127.0
Other, net	0.9	18.7	21.5
Other, net	(41.9)	(13.5)	0.2
Net cash used in investing activities	(18,092.2)	(5,619.9)	(4,030.6)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	32,443.4	3,760.8	2,310.8
Repayment of revolving line of credit, long term and short term borrowings	(16,404.3)	(3,110.9)	(1,461.8)
Repayment of debt acquired through business combinations	0.0	0.0	(551.5)
Proceeds from ViroPharma call options	0.0	0.0	346.7
Payment of dividend	(171.3)	(134.4)	(121.2)
Debt issuance costs	(172.3)	(24.1)	(10.2)
Contingent consideration payments	(8.0)	(101.2)	(15.2)
Proceeds from exercise of options	129.0	16.6	17.4
Other, net	9.3	32.2	39.5
Net cash provided by financing activities	15,825.8	439.0	554.5
Effect of foreign exchange rate changes on cash and cash equivalents	0.8	(3.0)	(9.3)
Net increase/(decrease) in cash and cash equivalents	393.3	(2,846.9)	743.0
Cash and cash equivalents at beginning of period	135.5	2,982.4	2,239.4
Cash and cash equivalents at end of period	528.8	135.5	2,982.4
Supplemental information associated with continuing operations:
Interest paid	(284.0)	(20.0)	(14.5)
Income taxes (paid)/received	(431.0)	(69.0)	194.4
Receipt of break fee	0.0	0.0	1,635.4
Shire Income Access Share Trust
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	150.6	127.7	112.8
Changes in operating assets and liabilities:
Net cash provided by operating activities	150.6	127.7	112.8
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities	0.0	0.0	0.0
CASH FLOWS FROM FINANCING ACTIVITIES:
Distributions made	150.6	127.7	112.8
Net cash provided by financing activities	(150.6)	(127.7)	(112.8)
Net increase/(decrease) in cash and cash equivalents	0.0	0.0	0.0
Cash and cash equivalents at beginning of period	0.0	0.0	0.0
Cash and cash equivalents at end of period	$ 0.0	$ 0.0	$ 0.0